NovaBridge Biosciences (NBP) 24th Annual Needham Virtual Healthcare Conference summary

Strategic transformation and operational focus

• Completed a major transformation in 2024, divesting China assets and shifting to a U.S.-focused, capital-efficient model with 24 employees.

• Now concentrates on three clinically active assets, with a cash runway projected into 2027.

• Divestiture and U.S. focus mitigate risks from tariffs and geopolitical tensions.

• Business development remains under consideration, but current priority is advancing the existing pipeline.

Pipeline highlights and clinical progress

• Lead asset, givastomig (Giva), is a Claudin18.2 4-1BB bispecific antibody for front-line gastric cancer, showing strong efficacy and safety in early studies.

• Giva demonstrated notable monotherapy activity and a favorable safety profile compared to competitors, with low rates of severe adverse events.

• Dose escalation and expansion studies for Giva are ahead of schedule, with key data readouts expected in late 2024 and early 2025.

• Uliledlimab (Uli), a CD73 antibody, is on hold in the U.S. pending data from a partner's randomized study in China, expected in 2026.

• Ragistomig (Ragi), a PD-L1 4-1BB bispecific, showed promising activity in IO-refractory solid tumors; further dose optimization studies are ongoing.

Competitive positioning and market opportunity

• Giva's design enables combination with standard of care without altering existing regimens, a key advantage over ADCs and T-cell engagers.

• Giva targets a broader patient population than current market leader Zolbetuximab, with potential expansion into other GI cancers.

• Intellectual property protection for Giva extends to 2040–2045.

• Uliledlimab offers superior CD73 inhibition compared to competitors, with biomarker-driven patient selection.

• Ragi outperformed a leading competitor in objective response rate for heavily pretreated patients.